key: cord-0983370-ux3sjtu1 authors: Ances, Beau M.; Newman, Nancy J.; Balcer, Laura J. title: Autoimmunity – Multiple Sclerosis date: 2007-05-09 journal: Measuring Immunity DOI: 10.1016/b978-012455900-4/50307-x sha: 5005d6b72b832c2f442243399ac842b563bfa591 doc_id: 983370 cord_uid: ux3sjtu1 nan Dreams are nothing but incoherent ideas, occasioned by partial or imperfect sleep. Benjamin Rush (1746 Rush ( -1813 EPIDEMIOLOGY MS is a common cause of neurological disability in middle-aged adults. This disease affects over one million people worldwide and is very common within the USA (Minden et al., 1993; Pugliatti et al., 2002; O'Connor et al., 2002) . Age, sex, race, geographical latitude, genetics and environmental exposure are risk factors for developin 9 MS. The median age of onset of MS is approximately 24 years of age (Minden et al., 1993) with a female to male ratio of two to one (O'Connor et al., 2002) . The mean age of death of MS patients is 58 years old, compared to the general national average in the USA of 72 years old (Minden et al., 1993) . Within the USA, MS is observed more often in Caucasians compared to African-Americans (Minden et al., 1993) . However, the typical clinical course is more severe within African-Americans who are affected (Pugliatti et al., 2002) . In regard to geographical patterns, a higher incidence of MS occurs when moving either more north or south of the equator, especially in countries with colder climates (Pugliatti et al., 2002) . This latitude effect is also present within the USA as the incidence of MS is highest within the upper Midwest and Northeast compared to the South (Minden et al., 1993) . Family studies have shown that genetic factors contribute to MS (Sadovnick, 2002; Herrera and Ebers, 2003; Measuring Immunity, edited by Michael -C Lotze and Angus W. Thomson ISBN 0-~ 2-455900-X, London Chapter 45 Kenealy et al., 2003; Wilier et al., 2003) . The risk for developing MS within dizygotic twins is the same as for other siblings (3-5 per cent). However, the risk for monozygotic twins is greater than 30 per cent (O'Connor et al., 2002; Wilier et al., 2003) . A greater than 10-fold increased risk of developing MS exists within individuals having certain human leukocyte antigens (HLA) genotypes (O'Connor et al., 2002; Sadovnick, 2002; Herrera and Ebers, 2003; Kenealy et al., 2003) . The major predisposing associated haplotype is HLA-DR2 in cellular typing nomenclature (DR15,DQ6 by serology and DRB5*0101-DQAI*0102-DQBI*0602 by sequence-based terminology) (Haegert and Francis, 1993; Hillert, 1994) . Even though an association between HLA class II DRB1*15 and DRB1*17 alleles and MS has been seen in individuals of northern European and Mediterranean descent, the presence of these haplotypes does not preclude the development of MS (Sadovnick, 2002; Herrera and Ebers, 2003; Kenealy et al., 2003) . Genetic interactions may also occur between certain haplotypes and certain T cell receptors, immunoglobulins and tumor necrosis factors which may lead to an increased chance of developing MS (O'Connor et al., 2002; Alizadeh et al., 2003) . Not only genetic but also one or more exogenous or environmental factors may influence the development of MS (O'Connor et al., 2002) . Although twin studies have provided strong evidence for genetic factors in the development of MS, the concordance rate for monozygotic twins has never been demonstrated to be greater than 40 per cent (Compston and Ebers, 1990; Sadovnick, 2002; Wilier et al., 2003) . Thus, at least 60 per cent of persons with an identical twin who has MS will not develop the disease. Certain foods, toxins, psychological stress, anesthesia, surgery and physical trauma have been implicated in the development of MS (O'Connor et al., 2002) . However, no direct causal relationships have been proven to date. Overall, it is believed that both genetic and environmental factors are responsible for the subsequent development of MS within a susceptible individual (O'Connor et al., 2002) . The resulting disability that results from MS leads to a major burden not only to the affected individual but also to the health care system and society (Whetten-Goldstein etal., 1998). Loss of myelin due to inflammation with limited subsequent remyelination are the two cardinal features of MS (Noseworthy et al., 2000) . Breakdown of the blood-brain barrier is typically observed with early inflammatory changes (Smith et al., 1993) . Immunocytochemical studies of active MS lesions have shown damage to vascular walls with intramural deposition of complement on smooth muscle components as well as protein-rich leakage (Noseworthy et al., 2000) . These abnormalities can occur within hours to days of an acute attack and slowly resolve over subsequent weeks to months (Poser, 1986) . Typical pathological findings seen in MS are plaques containing inflammatory cells scattered throughout the affected parenchyma and arranged in cuffs around blood vessels (Figure 45.1) . Inflammatory cells that are stimulated during an acute flare include macrophages, lymphocytes, large mononuclear cells and plasma cells (Prineas and Wright, 1978; Tourbah et al., 1993) . In MS macrophages are immunologically active and can stimulate T cells leading to the subsequent production of large quantities of cytokines and inflammatory mediators (Hafler and Weiner, 1995; Hohlfeld et al., 1995; Martin and McFarland, 1995; O' Connor et al., 2000) . These cytokines can be either proor anti-inflammatory in nature (Hafler and Weiner, 1995) with a T cell either stimulatory or inhibitory depending on surrounding environment factors (Hafler and Weiner, 1995; Hohlfeld, 1997) . Axonal loss has also shown to be a key factor in the pathogenesis of MS and is responsible for part of the irreversible clinical impairment and disability (O'Connor et al., 2002) . Axonal loss could stem from: 1 direct autoimmune attack against axons 2 a 'bystander injury' due to exposure of axons to immune attack following demyelination 3 degeneration of axons as a result of chronic demyelination 4 primary degeneration of axons, stimulating a secondary inflammatory response (Trapp et al., 1999; Lassmann, 2003) . The importance of these potential associated mechanisms remains to be determined. The exact etiology of MS remains unknown, but it is believed that this disease most likely results from a viral infection. These organisms can induce disturbances within a previously competent or compromised immune system (Allen and Brankin, 1993; Cook et al., 1995; O'Connor et al., 2002) . MS may either be due to infection by viruses that directly induce neurological dysfunction from the onset or result from reactivation later in life. A number of organisms or their nucleic acids have been observed within the CSF or brain parenchyma of patients with MS (Booss and Kim, 1990; O'Connor et al., 2002) . These organisms include mycoplasma (Cevassut, 1930 ), protozoa (Bequignon, 1956 ), spirochetes (ichelson, 1957 , as well as a number of both DNA and RNA viruses, such as herpes simplex viruses types 1, 2 and 6 (Sanders et al., 1996) , rabies virus (Bychkova, 1964) , parainfluenza virus type I (ter Meulen et al., 1972 ) , coronavirus (Talbot et al., 1996) , canine distemper virus (Rohowsky-Kochan et al., 1995) , measles virus (Haase et al., 1981) , human immunodeficiency virus type 1 (HIV-1) (Berger et al., 1989) and human T lymphotrophic virus type I (HTLV-I) (Salmi et al., 1983; Greenberg et al., 1989) . However, none of the above organisms have been successfully isolated from large groups of clinically definite MS patients. Furthermore, within MS patients infected with these organisms, levels did not correlate with disease activity (O'Connor etal., 2002) . Despite the lack of definitive evidence of a viral source for MS, it is commonly believed that one or more viruses may be responsible for the development of MS within certain genetically susceptible individuals (Allen and Brankin, 1993; Cook et al., 1995) . One hypothesis for the The main side effects of interferons are flu-like symptoms and depression that tend to diminish with time. Periodic laboratory evaluations including liver enzymes, complete white blood cell counts and thyroid function tests should be performed every 3-6 months. All of the interferons are capable of stimulating the production of neutralizing antibodies that can limit the efficacy of these agents (Sorensen et al., 2003) . The risk of antibody formation over 18 months of treatment is highest with Betaseron, intermediate with Rebif and lowest with Avonex (Bertolotto et al., 2003) . Glatiramer acetate (Copaxone), a daily subcutaneous injectable synthetic polymer, has been shown to have some positive effects in a small double-blind trial of RRMS (Bornstein et al., 1987) . Studies have shown a lower relapse rate and a significant reduction in the number of new T2 lesions compared to placebo. Side effects can include local injection site reactions and transient systemic post-injection reactions such as chest pain, flushing, dyspnea, palpitations and/or anxiety. No laboratory monitoring is necessary and no neutralizing antibodies have been detected. There are now a number of medications approved by the US Food and Drug Administration for the treatment of RRMS. There are no clear guidelines, nor is there strong evidence for choosing one drug versus another (Galetta et al., 2002) . After making a diagnosis of MS the patient should be started on one of the medications listed above. MS patients should be notified that these therapies primarily slow the disease course but are not a cure. These drugs are typically continued indefinitely unless side effects are Intolerable or the patient begins to fail in terms of response, after which use of another agent can be considered. Genetic interaction of CTLA-4 with HLA-DR15 in multiple sclerosis patients Pathogenesis of multiple sclerosis -the Immune diathesis and the role of viruses Interferon beta In multiple sclerosis (editorial; comment) MRI in the diagnosis and management of multiple sclerosis Visual evoked responses in the diagnosis and management of patients suspected of multiple sclerosis A randomized, controlled trial of corticosteroids In the treatment of acute optic neuritis The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis Brain magnetic resonance imaging in acute optic neuritis: Experience of The Optic Neuritis Study Group Optic Neuritis Treatment Trial. One-year follow-up results The course of visual recovery after optic neuritis: experience of the Optic Neuritis Treatment Trial Prediction of neuropsychological Impairment In multiple sclerosis: comparison of conventional magnetic resonance imaging measures of atrophy and lesion burden De I'etlologle de la sclerose en plaques Multiple sclerosis-like Illness occurring with human immunodeficiency virus Infection Persistent neutralizing antibodies abolish the Interferon beta bioavailability in MS patients Optic neuritis Evidence for a viral etiology of multiple sclerosis Central nervous system demyellnation presenting as a mass lesion: A diagnostic challenge A pilot trial of Cop 1 in exacerbatlng-remitting multiple sclerosis Spinal cord abnormalities In recently diagnosed MS patients: added value of spinal MRI examination A comparison of clinical neuro-ophthalmological findings and pattern shift evoked potentials in multiple sclerosis Viruses isolated from patients with encephalomyelitis and multiple sclerosis. Communication I: pathogenic and antigenic properties Interferon /3-1a for optic neuritis patients at high risk for multiple sclerosis Baseline MRI characteristics of patients at high risk for multiple sclerosis: results from the CHAMPS trial The aetiology of disseminated sclerosis Endogenous retroviruses and MS: using ERV's as disease markers The genetics of multiple sclerosis Total lymphoid irradiation (TLI) and low-dose prednisone (LDP) in progressive multiple sclerosis (PMS) Evaluation of patients with multiple sclerosis by evoked potentials and magnetic resonance imaging: A comparative study Application of the new McDonald Criteria to patients with clinically isolated syndromes suggestive of multiple sclerosis Chemical pathology of acute demyelinating lesions and its correlation with disability Every-other-day interferon beta-1 b versus once-weekly interferon beta-la for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN) The contribution of magnetic resonance imaging to the diagnosis of multiple sclerosis Axonal damage in acute multiple sclerosis lesions The impact of fatigue on patients with multiple sclerosis Acute demyelinating optic neuritis Cerebrospinal fluid IgG profiles and multiple sclerosis in Japan The Controlled High-Risk Avonex Multiple Sclerosis Trial (CHAMPS Study) Immunomodulatory agents for the treatment of relapsing multiple sclerosis: a systematic review Bilateral internuclear ophthalmoplegia in multiple sclerosis Detection of sequences homologous to retroviral DNA in multiple sclerosis by gene amplification Perspectives on multiple sclerosis Measles virus nucleotide sequences: Detection by hybridization in situ HLA-DQ polymorphisms do not explain HLA class II associations with multiple sclerosis in two Canadian groups Immunologic mechanisms and therapy in multiple sclerosis Pupil size and the pattern evoked visual response Cognitive deficits and emotional dysfunction in multiple sclerosis Progress in deciphering the genetics of multiple sclerosis Human leukocyte antigen studies in multiple sclerosis Biotechnological agents for the immunotherapy of multiple sclerosis: Principles, problems and perspectives The role of autoimmune T-lymphocytes in the pathogenesis of multiple sclerosis Multiple sclerosis with very late onset Late-onset MS Bipolar affective disorder prior to the onset of multiple sclerosis Cultivation of spirochaetes from spinal fluids with multiple sclerosis cases and negative controls Intramuscular interferon beta-la for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG) Intramuscular interferon beta-la therapy initiated during a first demyelinating event in multiple sclerosis The genetic epidemiology of multiple sclerosis Proton MR spectroscopy and magnetization transfer ratio in multiple sclerosis: correlative findings of active versus irreversible plaque disease Multiple sclerosis Initial results of the CHAMPIONS study, an open-label 5-year extension of the CHAMPS study. Presented at the 19th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Clinical studies of multiple sclerosis in Japan. I. A current appraisal of 83 cases Clinical manifestations of multiple sclerosis Epidemiology of multiple sclerosis Localized in vivo proton spectroscopy in the brain of patients with multiple sclerosis Axonal injury in multiple sclerosis: renewed interest in axonal destruction in MS (editorial) Optic nerve involvennent and diplopia as initial manifestations of multiple sclerosis Multiple sclerosis Visual loss: optic neuropathies Cerebrospinal fluid in multiple sclerosis for the National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis Symptoms and signs The ocular manifestations of multiple sclerosis. 1. Abnormalities of the afferent visual system Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis The multiple sclerosis lesion Immunological aspects of experimental allergic encephalomyelitis and multiple sclerosis Proton magnetic resonance spectroscopy for metabolic characterization of plaques in multiple sclerosis Assessment of lesion pathology in multiple sclerosis using quantitative MRI morphometry and magnetic resonance spectroscopy Clinical and oculographic examinations of saccadic eye movements in the diagnosis of multiple sclerosis Clinical features Occurrence of oligoclonal bands in multiple sclerosis and other CNS diseases Multiple Sclerosis: a statistical portrait. A compendium of data on demographics, disability, and health services utilization in the United States Studies on disseminated sclerosis with special reference to symptomatology, course and prognosis The clinical spectrum of internuclear ophthalmoplegia in multiple sclerosis Contrast sensitivity in multiple sclerosis: a study in 35 patients with and without optic neuritis Multiple sclerosis Key issues in the diagnosis and treatment of multiple sclerosis The clinical profile of optic neuritis: experience of the Optic Neuritis Treatment Trial Visual function more than 10 years after optic neuritis: experience of the Optic Neuritis Treatment Trial Magnetic resonance imaging in clinically isolated lesions of the brain stem Health-related quality of life and depression in an Italian sample of multiple sclerosis patients Neuroimaging in multiple sclerosis Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group Pathogenesis of multiple sclerosis: A critical reappraisal New diagnostic criteria for multiple sclerosis: guidelines for research protocols Randomised double-blind placebo-controlled study of interferon beta-la in relapsing/ remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-la Subcutaneously in Multiple Sclerosis) Study Group The worldwide prevalence of multiple sclerosis Axonal dystrophy as a consequence of long-term demyelination Evoked Potentials in Psychology, Sensory Physiology and Clinical Medicine Effect of body temperature on visual evoked potential delay and visual perception in multiple sclerosis Eye movement disorders in multiple sclerosis and optic neuritis Canine distemper virus-specific antibodies in multiple sclerosis Multiple sclerosis and the mind The genetics of multiple sclerosis Intrathecal antibody synthesis to virus antigens in multiple sclerosis PPD-, PWM-, and PHA-induced interferon in stable multiple sclerosis: Association with HLA-Dw2 antigen and clinical variables Herpes simplex virus in postnnortenn nnultiple sclerosis brain tissue Behavioral disorders in nnultiple sclerosis, tennporal lobe epilepsy, and amyotrophic lateral sclerosis Pathogenesis of demyelination Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine-enhancing magnetic resonance imaging lesions Optic neuritis and multiple sclerosis Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis Myelin basic protein and human coronavirus 229E cross-reactive T cells in multiple sclerosis The relationship between diffuse axonal damage and fatigue in multiple sclerosis Fusion of cultured multiple-sclerosis brain cells with indicator cells: Presence of nucleocapsids and virion with isolation of parainfluenza-type virus Slowed abduction saccades in bilateral internuclear ophthalmoplegia Immunologie de la sclerose en plaques: Donnees recentes et perspectives therapeutiques Neurodegeneration in multiple sclerosis: relationship to neurological disability Contrast sensitivity and other vision tests in the Optic Neuritis Treatment Trial The measurement of fatigue in patients with multiple sclerosis. A multidimensional comparison with patients with chronic fatigue syndrome and healthy subjects The relationship between levels of cerebrospinal fluid myelin basic protein and IgG measurements in patients with multiple sclerosis A comprehensive assessment of the cost of multiple sclerosis in the United States Twin concordance and sibling recurrence rates in Multiple Sclerosis Visual-evoked response differentiation of ischemic optic neuritis from the optic neuritis of multiple sclerosis The significance of serum oligoclonal bands in neurological diseases A study of oligoclonal band negative multiple sclerosis This chapter was revised from Multiple Sclerosis and Related Demyelinating Diseases by Nancy J. Newman and Laura J. Balcer in Walsh and Hoyt's Clinical Neuroophthalmology(2004).